Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTX NASDAQ:FULC NASDAQ:IKT NASDAQ:IMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$4.89+0.5%$4.32$3.27▼$6.95$285.35M2.89213,784 shs260,547 shsFULCFulcrum Therapeutics$3.66-1.9%$5.66$2.83▼$15.74$248.54M2.935.28 million shs2.42 million shsIKTInhibikase Therapeutics$2.02+4.9%$1.79$1.33▼$2.26$254.82M0.92773,394 shs1.52 million shsIMAImageneBio$5.90-2.8%$5.75$3.94▼$18.00$64.67M0.7212,934 shs8,232 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics+15.17%+16.27%+13.55%+1.67%+0.41%FULCFulcrum Therapeutics-1.84%-1.06%-46.10%-51.37%-47.46%IKTInhibikase Therapeutics+1.31%+4.89%+10.29%+14.88%+192,999,900.00%IMAImageneBio+3.14%+1.34%+3.23%+21.40%-62.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$4.89+0.5%$4.32$3.27▼$6.95$285.35M2.89213,784 shs260,547 shsFULCFulcrum Therapeutics$3.66-1.9%$5.66$2.83▼$15.74$248.54M2.935.28 million shs2.42 million shsIKTInhibikase Therapeutics$2.02+4.9%$1.79$1.33▼$2.26$254.82M0.92773,394 shs1.52 million shsIMAImageneBio$5.90-2.8%$5.75$3.94▼$18.00$64.67M0.7212,934 shs8,232 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics+15.17%+16.27%+13.55%+1.67%+0.41%FULCFulcrum Therapeutics-1.84%-1.06%-46.10%-51.37%-47.46%IKTInhibikase Therapeutics+1.31%+4.89%+10.29%+14.88%+192,999,900.00%IMAImageneBio+3.14%+1.34%+3.23%+21.40%-62.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 2.88Moderate Buy$11.43133.95% UpsideFULCFulcrum Therapeutics 1.75Reduce$8.20124.04% UpsideIKTInhibikase Therapeutics 3.11Buy$5.40166.80% UpsideIMAImageneBio 2.00Hold$26.50349.15% UpsideCurrent Analyst Ratings BreakdownLatest IMA, FULC, IKT, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026IKTInhibikase Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight6/2/2026FULCFulcrum Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.006/2/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$4.006/2/2026FULCFulcrum Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.006/2/2026FULCFulcrum Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026FULCFulcrum Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$4.006/2/2026FULCFulcrum Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$3.006/2/2026FULCFulcrum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.005/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$28.22M10.16N/AN/A($1.92) per share-2.54FULCFulcrum Therapeutics$80M3.05N/AN/A$6.45 per share0.57IKTInhibikase TherapeuticsN/AN/AN/AN/A$2.30 per shareN/AIMAImageneBioN/AN/AN/AN/A$11.91 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)FULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)IKTInhibikase Therapeutics-$48.26M-$0.43N/AN/AN/AN/A-41.31%-38.98%N/AIMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/ALatest IMA, FULC, IKT, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IKTInhibikase Therapeutics-$0.10-$0.10N/A-$0.10N/AN/A5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A2.922.92FULCFulcrum TherapeuticsN/A34.3334.33IKTInhibikase TherapeuticsN/A30.1430.14IMAImageneBioN/A18.3918.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%FULCFulcrum Therapeutics89.83%IKTInhibikase Therapeutics3.81%IMAImageneBio75.00%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics9.02%FULCFulcrum Therapeutics7.30%IKTInhibikase Therapeutics7.10%IMAImageneBio2.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12058.71 million53.42 millionOptionableFULCFulcrum Therapeutics10066.63 million61.77 millionOptionableIKTInhibikase Therapeutics6132.03 million122.66 millionN/AIMAImageneBio7010.65 million10.42 millionNot OptionableIMA, FULC, IKT, and FHTX HeadlinesRecent News About These CompaniesImageneBio, Inc. Common StockJune 27 at 8:34 AM | fxempire.comFImageneBio, Inc. Common Stock (IMA) SEC FilingsJune 25, 2026 | nasdaq.comImageneBio Shareholders Back Directors and Governance ProposalsJune 17, 2026 | tipranks.comImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkMay 27, 2026 | globenewswire.comImageneBio (IMA) price target decreased by 18.75% to 13.26May 15, 2026 | msn.comImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateMay 7, 2026 | globenewswire.comImageneBio Inc.April 13, 2026 | barrons.comIMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally?April 13, 2026 | msn.comImageneBio $30 Million Private Placement Ignites StockApril 13, 2026 | benzinga.comImageneBio, Inc. Secures $30 Million in Private Placement Led by Coastlands Capital to Advance IMG-007 DevelopmentApril 13, 2026 | quiverquant.comQImageneBio Announces $30 Million Private Warrant FinancingApril 13, 2026 | tipranks.comImageneBio Announces $30 Million Private PlacementApril 13, 2026 | globenewswire.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 17, 2026 | globenewswire.comImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company UpdateMarch 10, 2026 | globenewswire.comImageneBio to Participate in Leerink Global Healthcare ConferenceFebruary 26, 2026 | globenewswire.comImageneBio announces immediate resignation of board directorFebruary 17, 2026 | tipranks.comImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical OfficerFebruary 10, 2026 | globenewswire.comImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market CapDecember 31, 2025 | finance.yahoo.comInsider Buying: ImageneBio (NASDAQ:IMA) Director Acquires 16,000 Shares of StockDecember 30, 2025 | insidertrades.comImageneBio (IMA) price target decreased by 94.20% to 16.32December 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat to Expect From Q2 Earnings as Tech Strength BroadensBy Thomas Hughes | June 14, 2026Planet Labs: Coming Back Down to EarthBy Chris Markoch | June 8, 2026Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreBy Leo Miller | June 19, 2026SpaceX IPO Fears Are Overblown, But the AI Bet Is RealBy Bridget Bennett | June 11, 2026Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?By Sam Quirke | June 6, 2026IMA, FULC, IKT, and FHTX Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$4.88 +0.03 (+0.51%) Closing price 03:59 PM EasternExtended Trading$4.88 -0.01 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Fulcrum Therapeutics NASDAQ:FULC$3.66 -0.07 (-1.88%) Closing price 04:00 PM EasternExtended Trading$3.70 +0.04 (+1.09%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Inhibikase Therapeutics NASDAQ:IKT$2.02 +0.09 (+4.87%) Closing price 03:59 PM EasternExtended Trading$1.99 -0.03 (-1.68%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.ImageneBio NASDAQ:IMA$5.90 -0.17 (-2.80%) Closing price 04:00 PM EasternExtended Trading$5.93 +0.03 (+0.44%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
